UNSPSC 51351525: Nomegestrol acetate

This classification denotes a therapeutic progestin C23H30O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83J78V5W05, chemically known as 6-methyl-3,20-dioxo-19-norpregna-4,6-dien-17-yl acetate, but more generally known as nomegestrol acetate, which bears US NIH Compound Identifier 91668. European Medicines Agency schedules Nomegestrol acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03449MIG.

Most nations, for tariff and trade purposes, schedule nomegestrol acetate under HS 29372300 and SITC 54153. As of Q4 2014, NOMEGESTROL ACETATE remains US FDA's Preferred Term for this commodity. Nomegestrol acetate bears US NLM identifiers UMLS ID C0132749 and NCI Concept Code C87244. SMILES: CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@H]4C1=CC(=O)CC4.

UNSPSC 51351525 Nomegestrol acetate is a Commodity code covering hormonal contraceptive pharmaceuticals supplied through state and local government cooperative purchasing agreements. State and local governments procure nomegestrol acetate and related generic pharmaceuticals through multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions and their healthcare facilities, schools, correctional institutions, and social service agencies. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and similar vehicles serve as the primary procurement mechanism, with vendors supplying products through authorized pharmaceutical wholesalers under negotiated pricing frameworks. Issuers include state departments of administration, cooperative purchasing organizations administered by state procurement offices, and member jurisdictions spanning multiple states. Solicitations emphasize compliance with Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) requirements, FDA regulatory standards, and contractual relationships with specified authorized wholesalers maintaining chargeback systems.

MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon, with proposals due March 26, 2026. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with detailed product specifications including National Drug Codes, SKUs, UPCs, strength, dosage form, and manufacturing locations. Evaluation criteria weight price competitiveness at 75 percent, with remaining points distributed across fixed pricing (10 percent), compliance with administrative data format (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Contract awards are effective July 1, 2026, for an initial two-year term with optional extensions, and vendors must maintain commercial general liability insurance of $5,000,000 per occurrence and network security and privacy liability of $2,000,000.